title: [Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and antiaggregant].
abstract: OBJECTIVE
  Study of the tolerance and pharmacodynamic and pharmacokinetic characteristics of ascolong, a new buccal dosage form of aspirin containing a very low dose of acetylsalicylic acid (ASA): 12.5 mg.
  
  
  METHODS
  The study was carried out in 43 healthy men (assessment of the drug tolerance) and 19 male patients with coronary disease or cerebrovascular disorders. In 10 patients the antiaggregant efficacy of ascolong administered once or regularly (for 2 weeks) in a dose of 12.5 mg was compared with placebo, in 9 patients a random cross study of 2-week courses of ascolong and Russian aspirin tablets in a dose of 100 mg was carried out. Platelet aggregation was assessed on days 1 and 14 of each course before and 2, 4, and 24 h after the drug intake.
  
  
  RESULTS
  Ascolong containing a very low dose of ASA exerts a reliable antiaggregant effect after a single and regular intake, although this effect is less manifest than after aspirin tablets. Profiles of ASA concentrations in the blood were studied. Transbuccal entry of ASA in systemic circulation decelerated its metabolism into a less active metabolite, salicylic acid, due to which fact the ASA microdose had an expressed antiaggregant effect. The drug was sufficiently well tolerated.
  
  
  CONCLUSIONS
  The new buccal film form of aspirin containing a very low dose of ASA possesses a good antiaggregant effect and is promising in subjects with contraindications to oral intake of aspirin.
authors.forename: E V
authors.initials: EV
authors.lastname: Kokurina
authors.forename: Z A
authors.initials: ZA
authors.lastname: Suslina
authors.forename: G L
authors.initials: GL
authors.lastname: Khromov
authors.forename: A B
authors.initials: AB
authors.lastname: Davydo
authors.forename: V I
authors.initials: VI
authors.lastname: Metelitsa
authors.forename: V G
authors.initials: VG
authors.lastname: Ionova
authors.forename: M M
authors.initials: MM
authors.lastname: Tanashian
authors.forename: E G
authors.initials: EG
authors.lastname: Demina
authors.forename: E V
authors.initials: EV
authors.lastname: Bochkareva
authors.forename: V G
authors.initials: VG
authors.lastname: Belolipetskaia
authors.forename: A D
authors.initials: AD
authors.lastname: Deev
authors.forename: N G
authors.initials: NG
authors.lastname: Kucheriaeva
authors.forename: S I
authors.initials: SI
authors.lastname: Zidra
authors.forename: N N
authors.initials: NN
authors.lastname: Gorin
authors.forename: D O
authors.initials: DO
authors.lastname: Rumiantsev
mesh_terms: D000278:Administration, Buccal; D001241:Aspirin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003327:Coronary Disease / Q000188:drug therapy / Q000378:metabolism; D018592:Cross-Over Studies; D004304:Dosage Forms; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012449:Safety; D016896:Treatment Outcome
chemical_list: D004304:Dosage Forms; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
vernacular_title: Aksolong: novaia bukkal'naia forma atsetilsalitsilovoĭ kisloty dlia primeneniia v kachestve antiagreganta.